FDG-PET/CT Scans in Patients With Stage IIIB or Stage IV NSCLC Undergoing Chemotherapy
Status:
Terminated
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 (^18FDG) positron emission
tomography (PET)/CT scans, may help doctors predict a patient's response to treatment and
help plan the best treatment.
PURPOSE: This clinical trial is studying ^18FDG PET/CT scans to see how well they predict
response in patients undergoing chemotherapy for stage IIIB or stage IV non-small cell lung
cancer.